Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Stanford University researchers have developed aptamer-antibody chimeras that achieve dynamic, sensitive, and specific biomolecule sensing beyond the capacity of antibodies or aptamers alone.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford researchers in the Weissman lab have developed an engineered protein that blocks the function of the CD47 mimics pathogens use to evade the immune system.
Stanford researchers at the Sattely Lab have discovered six podophyllotoxin biosynthetic genes and their polypeptide products from the plant, Podophyllum hexandrum (mayapple).
Researchers in Dr. Karl Deisseroth's lab have engineered a channelrhodopsin variant that can be stimulated by red light and has fast stimulation frequencies. In neurons, channelrhodopsins are light activated protein channels that induce action potential firing.
Stanford researchers have developed a highly specific, tunable system to improve the safety, efficacy and deliverability of gene therapy vectors and other biological therapies.